Article Text

Download PDFPDF
Safety and Efficacy of Extended Bevacizumab Therapy in Elderly (≥70 Years) Versus Younger Patients Treated for Newly Diagnosed Ovarian Cancer in the International ROSiA Study
  1. Frédéric Selle, MD*,
  2. Nicoletta Colombo, MD,
  3. Jacob Korach, MD,
  4. César Mendiola, MD§,
  5. Andres Cardona, MSc,
  6. Youssef Ghazi, MD and
  7. Amit M. Oza, MD
  1. * Groupe Hospitalier Diaconesses Croix Saint-Simon and Alliance Pour la Recherche en Cancérologie, Paris, France;
  2. European Institute of Oncology and University of Milan-Bicocca, Milan, Italy;
  3. Sheba Medical Center, Tel Hashomer, Israel;
  4. § Hospital Universitario 12 de Octubre, Madrid, Spain;
  5. F. Hoffmann-La Roche Ltd, Basel, Switzerland; and
  6. Princess Margaret Hospital, University of Toronto, Toronto, ON, Canada.
  1. Address correspondence and reprint requests to Frédéric Selle, MD, Service d'Oncologie Médicale, Groupe Hospitalier Diaconesses Croix Saint Simon and Alliance Pour la Recherche en Cancérologie, 125 rue d'Avron, 75020 Paris, France. E-mail: Fselle{at}


Objective The single-arm ROSiA study explored an extended duration of frontline bevacizumab-containing therapy for ovarian cancer. Post hoc analyses explored safety and efficacy according to age.

Patients and Methods After primary debulking surgery, patients with stage IIB–IV or grade 3 stage I–IIA ovarian cancer received 4–8 cycles of paclitaxel [weekly or every 3 weeks (q3w)], carboplatin AUC 5–6 q3w, and bevacizumab 15 (or 7.5) mg/kg q3w, followed by single-agent bevacizumab until progression or for up to 24 months. The primary end point was safety; progression-free survival (PFS) was a secondary end point.

Results Of 1021 patients treated, 121 (12%) were aged 70 years or older and 44 (4%) were 75 years or older. Compared with younger patients, more patients aged 70 years or older had hypertension at baseline, stage IV disease, and Eastern Cooperative Oncology Group performance status 1 or above. Bevacizumab was continued for more than 15 months in 49% of older versus 53% of younger patients. Older patients experienced higher incidences of all-grade anemia (44% vs 32%), diarrhea (35% vs 25%), and asthenia (22% vs 12%), and grade ≥3 hypertension (41% vs 22%) and thromboembolic events (7% vs 2%) compared with younger patients. Fatal bevacizumab-related adverse events occurred in 1 (0.8%) older versus 5 (0.6%) younger patients. Median PFS was 23.7 (95% confidence interval, 18.6–27.9) versus 25.6 (95% confidence interval, 23.7–28.4) months in patients aged 70 or older versus those younger than 70 years, respectively.

Conclusion Bevacizumab-treated patients aged 70 years or older had higher incidences of anemia, low-grade diarrhea, and asthenia, and grade ≥3 hypertension and thromboembolic events than those younger than 70 years, but no other relevant increase in toxicity. Median PFS of approximately 2 years is similar to that in younger patients despite the worse prognosis. Older age should not preclude bevacizumab therapy for ovarian cancer in carefully selected patients aged 70 years or older. Given the higher background hypertension prevalence, elderly patients should be monitored more closely while receiving bevacizumab.

  • Bevacizumab
  • Ovarian cancer
  • Elderly

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.